RESUMO

Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) accounts for approximately 5% of Hodgkin's lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy.

Assuntos

Anticorpos Monoclonais/uso terapêutico , Doença de Hodgkin/tratamento farmacológico , Idoso , Anticorpos Monoclonais Murinos , Antineoplásicos/uso terapêutico , Quimioterapia Adjuvante , Feminino , Doença de Hodgkin/classificação , Doença de Hodgkin/imunologia , Humanos , Ativação Linfocitária/efeitos dos fármacos , Recidiva , Rituximab